Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Status:
RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
This research study is studying if the investigational drug, Pembrolizumab, in combination with chemotherapy helps primary central nervous system lymphoma with acceptable side effects.
This research study involves a combination of the below drugs:
* Pembrolizumab (a type of monoclonal antibody)
* Methotrexate (a type of anti-metabolite)
* Temozolomide (a type of alkylating agent)
* Rituximab (a type of antibody)
Phase:
PHASE1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Merck Sharp & Dohme LLC
Treatments:
Immunoglobulin G Methotrexate pembrolizumab Rituximab Temozolomide